ALNOV:EPA
Novacyt SA
0,46 €
arrow_upward
+0,54%(+0,0025) 1 d.
21. okt., 17:35:18 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,46 €
Augsta
0,46 €
Zema
0,46 €
Tirgus kapitalizācija
34,14 milj.
Vid. apjoms
235,63 tūkst.
Apjoms
37,89 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,37 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,46 €
Augsta
0,46 €
Zema
0,46 €
Tirgus kapitalizācija
34,14 milj.
Vid. apjoms
235,63 tūkst.
Apjoms
37,89 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,37 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
www.stl.news
·
pirms 10 minūtēm
Stock Market Today: Nasdaq Leads Wall Street Rally
Yahoo Finance
·
pirms 40 minūtēm
Direct Digital Holdings Announces Intention to Voluntarily Delist from Nasdaq and Deregister Its Class A Common Stock with the SEC
TradingView
·
pirms 26 minūtēm
S&P 500, Nasdaq Gain, Powered By Meta, Tesla Stock — SPCX, META, TSLA, SKYD, IBM In Focus
Reuters
·
pirms 24 minūtēm
Nasdaq leads Wall Street gains as SpaceX, Super Micro aid AI sentiment
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
Sektors-
Tīmekļa vietnenovacyt.com